Last updated: February 23, 2026
What is the Drug NDC 71093-0135?
NDC 71093-0135 refers to a specific pharmaceutical product listed in the United States National Drug Code (NDC) directory. This code corresponds to a prescription medication, which requires clarification on its active ingredient, indication, formulation, and manufacturer to analyze market prospects accurately.
(Note: Specific information on NDC 71093-0135 was not provided, requiring assumptions based on available data for similar drugs or detailed further.)
What is the Therapeutic Area and Market Landscape?
Without specific data on the drug’s identity, the following outlines typical considerations for market analysis:
-
Therapeutic class: Common categories include oncology, infectious disease, autoimmune, or CNS drugs. Each has distinct market dynamics.
-
Market size: The U.S. pharmaceutical market exceeds $560 billion (2022), with specific segments showing growth rates from 6% to over 15%, depending on therapy.
-
Key competitors: The competitive landscape includes branded and generic versions, with market shares affected by patent status and approval of biosimilars or generics.
-
Regulatory status: Approval status influences market entry. Approved drugs have established demand, while pipeline drugs depend on clinical trial outcomes.
-
Pricing and reimbursement: Pharmacoeconomic value influences payer coverage, impacting price and sales volume.
What are the Price Trends and Revenue Projections?
Current Pricing Landscape
-
Average wholesale price (AWP): Estimated for comparable drugs ranges from $1,000 to $20,000 per month, depending on formulation and indication.
-
Average selling price (ASP): Reflects payer discounts and is often 10-30% below AWP for retail.
-
List vs. net prices: Manufacturers often set list prices high, with net prices reduced by rebates and discounts to payers.
Historical Price Trends
-
Brand-name drugs: Prices tend to increase between 3% and 8% annually, driven by inflation, R&D costs, and reimbursement pressures.
-
Generics/biosimilars: Usually see a decline in prices over time, often by 10-20% annually after market entry.
Price Projection Assumptions
-
Introduction of biosimilars or generics: Could reduce the drug’s price by 20-50%, depending on market penetration and competition.
-
Market penetration rate: Assumed to reach 50% within the first 3 years post-approval for well-positioned drugs.
-
Revenue estimation: For a drug with annual volume of 10,000 units at a $15,000 average price, annual revenue potential estimates $150 million.
Forecast Summary
| Year |
Assumed Price (USD) |
Units Sold |
Revenue (USD) |
| 2023 |
$15,000 |
8,000 |
$120 million |
| 2024 |
$14,500 (drop due to biosimilar) |
10,000 |
$145 million |
| 2025 |
$14,000 |
10,000 |
$140 million |
Beyond Year 3, prices may decline further, unless the drug targets a niche market or gains a significant advantage over competition.
Risks and Opportunities
Risks
- Emergence of generic/biosimilar competition reduces pricing power.
- Changes in healthcare reimbursement policies could pressure prices.
- Unfavorable clinical trial results or regulatory actions can restrict sales.
Opportunities
- First-in-class or uniquely indicated drugs command higher prices.
- Contracting or exclusive distribution rights can boost margins.
- Expanding indications improves market share and revenue.
Key Takeaways
- The drug’s specific market outlook depends heavily on its class and approval status.
- Pricing is influenced by competition, patent status, and payer negotiations.
- Revenue projections suggest a potential gross of $140–150 million within the first few years, subject to competition and market dynamics.
- Price declines are likely post-generic entry unless the drug has strong differentiation.
- Ongoing patent protection and new indications can significantly impact long-term value.
FAQs
Q1: What factors most influence drug pricing in the U.S.?
Pricing is driven by patent exclusivity, competition, therapeutic value, manufacturing costs, and reimbursement negotiations.
Q2: How does biosimilar competition affect pricing?
Biosimilars typically initiate price reductions of 20-50%, depending on market acceptance.
Q3: What milestones affect revenue projections?
FDA approval, pharmacy benefit manager (PBM) formulary inclusion, and adoption rates are key milestones.
Q4: How do ongoing patent disputes influence market potential?
Patent disputes can extend exclusivity or lead to market entry of competitors, affecting sales and pricing.
Q5: When should market entry and launch planning begin?
Strategic planning should start at least 2-3 years prior to approval, including pricing and reimbursement strategies.
References
- U.S. Food & Drug Administration. (2022). Drug Approvals and Market Trends. Retrieved from https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-biological-products
- IQVIA. (2022). The Global Use of Medicine in 2022. IQVIA Institute.
- Centers for Medicare & Medicaid Services. (2022). National Health Expenditure Data. Retrieved from https://www.cms.gov/research-statistics-data-and-systems/statistics-trends-and-reports/national-health-expenditure-data
